Vanda Pharmaceuticals Inc.

As of June 30, 2026, Vanda Pharmaceuticals Inc. carries a market capitalization of 324.34M, placing it among publicly traded companies globally. Its enterprise value stands at 195.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vanda Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Vanda Pharmaceuticals Inc. has 60.45M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.69, and the price-to-book ratio stands at 1.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 195.50M versus a market cap of 324.34M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vanda Pharmaceuticals Inc. maintains a current ratio of 1.61, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vanda Pharmaceuticals Inc. posted a negative return on equity (ROE) of -77.81, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -53.00, reflecting losses generated across the asset base. The company generates approximately 383,976.80 in revenue per employee across its workforce of 491.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.02 indicates how many times Vanda Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vanda Pharmaceuticals Inc. recorded 85.48M in income tax expense. The company reported a pretax loss of -155.10M and -240.58M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Vanda Pharmaceuticals Inc.'s stock has declined approximately 21.48% over the past 52 weeks. The 50-day moving average sits at 4.33, while the 200-day moving average is 5.43.

Over the twelve months ended June 30, 2026, Vanda Pharmaceuticals Inc. generated 188.82M in revenue and converted that into -240.58M in net income, yielding earnings per share of -4.05. EBITDA reached -150.76M, while operating income came in at -162.52M.

As of June 30, 2026, Vanda Pharmaceuticals Inc. holds 148.83M in cash and equivalents against 19.98M in total debt, resulting in a net debt position of -48.91M. Total book value stands at 192.73M, with working capital of 87.93M providing operational flexibility.

Vanda Pharmaceuticals Inc. produced -124.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.34M in capital expenditures, free cash flow totaled -133.93M - equivalent to -2.25 per share.

Over the twelve months ended June 30, 2026, Vanda Pharmaceuticals Inc. posted a gross margin of 93.74, reflecting its pricing power and cost economics. The operating margin of -86.07 and net profit margin of -127.41 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -41.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vanda Pharmaceuticals Inc. shareholders.

As of June 30, 2026, Vanda Pharmaceuticals Inc. has an Altman Z-Score of -2.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.